Inhibition of GSK3 promotes replication and survival of pancreatic beta cells

被引:121
作者
Mussmann, Rainer [1 ]
Geese, Marcus [1 ]
Harder, Friedrich [1 ]
Kegel, Simone [1 ]
Andag, Uwe [1 ]
Lomow, Alexander [1 ]
Burk, Ulrike [1 ]
Onichtchouk, Daria [1 ]
Dohrmann, Cord [1 ]
Austen, Matthias [1 ]
机构
[1] DeveloGen AG, D-37079 Gottingen, Germany
关键词
D O I
10.1074/jbc.M609637200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent developments indicate that the regeneration of beta cell function and mass in patients with diabetes is possible. A regenerative approach may represent an alternative treatment option relative to current diabetes therapies that fail to provide optimal glycemic control. Here we report that the inactivation of GSK3 by small molecule inhibitors or RNA interference stimulates replication of INS-1E rat insulinoma cells. Specific and potent GSK3 inhibitors also alleviate the toxic effects of high concentrations of glucose and the saturated fatty acid palmitate on INS-1E cells. Furthermore, treatment of isolated rat islets with structurally diverse small molecule GSK3 inhibitors increases the rate beta cell replication by 2-3-fold relative to controls. We propose that GSK3 is a regulator of beta cell replication and survival. Moreover, our results suggest that specific inhibitors of GSK3 may have practical applications in beta cell regenerative therapies.
引用
收藏
页码:12030 / 12037
页数:8
相关论文
共 85 条
[1]   GLP-1 based therapy for type 2 diabetes [J].
Arulmozhi, DK ;
Portha, B .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 28 (1-2) :96-108
[2]   ADA Outstanding Scientific Achievement Lecture 2004 - Thirty years of investigating the autointmune basis for type 1 diabetes - Why can't we prevent or reverse this disease? [J].
Atkinson, MA .
DIABETES, 2005, 54 (05) :1253-1263
[3]   Therapeutic approaches to preserve islet mass in type 2 diabetes [J].
Baggio, LL ;
Drucker, DJ .
ANNUAL REVIEW OF MEDICINE, 2006, 57 :265-281
[4]   A novel approach to increase human islet cell mass while preserving β-cell function [J].
Beattie, GM ;
Montgomery, AMP ;
Lopez, AD ;
Hao, E ;
Perez, B ;
Just, ML ;
Lakey, JRT ;
Hart, ME ;
Hayek, A .
DIABETES, 2002, 51 (12) :3435-3439
[5]   Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade [J].
Beaulieu, JM ;
Sotnikova, TD ;
Yao, WD ;
Kockeritz, L ;
Woodgett, JR ;
Gainetdinov, RR ;
Caron, MG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (14) :5099-5104
[6]  
Bernal-Mizrachi E, 2001, J CLIN INVEST, V108, P1631, DOI 10.1172/JCI200113785
[7]   Endocrine pancreas plasticity under physiological and pathological conditions [J].
Bernard-Kargar, C ;
Ktorza, A .
DIABETES, 2001, 50 :S30-S35
[8]   Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418 [J].
Bhat, R ;
Xue, YF ;
Berg, S ;
Hellberg, S ;
Ormö, M ;
Nilsson, Y ;
Radesäter, AC ;
Jerning, E ;
Markgren, PO ;
Borgegård, T ;
Nylöf, M ;
Giménez-Cassina, A ;
Hernández, F ;
Lucas, JJ ;
Díaz-Nido, J ;
Avila, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (46) :45937-45945
[9]   Phosphorylation marks IPF1/PDX1 protein for degradation by glycogen synthase kinase 3-dependent mechanisms [J].
Boucher, MJ ;
Selander, L ;
Carlsson, L ;
Edlund, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (10) :6395-6403
[10]   Regulation of pancreatic beta-cell mass [J].
Bouwens, L ;
Rooman, I .
PHYSIOLOGICAL REVIEWS, 2005, 85 (04) :1255-1270